YUCAIPA, Calif., May 5, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer anticipating $200 million in revenues over the next five years, with an emerging new medical product line for the $4 billion U.S. and $8 billion global respiratory market, today announced that MedTrade TV has featured Ingens' new SMART Nasal Cannula in their new product pavilion segment for this week. Ingen's revenues have increased 126% in the past 60 days, and OEM partners continue to increase orders, as new Private Label contracts spawn more production.
MedTrade TV presents Ingen's new SMART Nasal Cannula in a video available on their home-page, http://www.medtrade.com/, for the medical professional community to view. Ingen is one of 300 exhibitors at MedTrade, the world's largest medical convention starting on May 11th, 2010, and is one of only a handful of companies, such as Phillips-Respironics, announcing new innovations which have been recognized within the medical industry. Ingen will be granted priority features throughout the three-day show at the Sands Expo and Convention Center in Las Vegas, Nevada.
The company's "Oxyview" is also a featured product in the June publication of HME (Home Medical Equipment) magazine's Respiratory & Sleep Management issue. The HME Media Group's audience includes HME providers, rehab technology suppliers, hospitals with HME, pharmacies selling HME, respiratory therapists, occupational/physical therapists, VA's, sleep labs and rehab centers. Respiratory & Sleep Management http://hmemediagroup.com/pages/about.aspx is a publication targeting respiratory providers and therapists. RM's specialties: Highly focused coverage on oxygen, sleep disorder and asthma issues, as well as the cutting-edge product technologies, evolving legislation, research, events and other forces driving the market.
"The MedTrade conference in conjunction with a scheduled TV interview on the Las Vegas Money Show couldn't have come at a better time, increasing our exposure to tens of thousands of medical professionals. We are rapidly increasing our sales, branding, and global distribution efforts," said Scott Sand, Ingen Technologies, Inc. Chairman and CEO. "We will keep shareholders updated in the weeks to come as we continue to progress and build value in our organization."
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.